Bunge Global SA (NYSE: BG) — A Scaled-Up Spread Business Priced at an All-Time High on Policy-Juiced Earnings

Author: Independent equity research Report date: July 10, 2026 Analyst framing: Fresh coverage / initiation

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information only — not investment advice. The analysis that follows the Price-Action section is written to be position-free and carries no recommendation or price target; the single exception is this opinion block.

Verdict: HOLD — quality-average business, full price. Don’t chase at the all-time high (~$114); accumulate on weakness toward ~$85–95 (≈1.0–1.1× book / ~10× a normalized ~$8 mid-cycle EPS). Not a short. Conviction: medium.

Bunge is a genuinely better company than it was three years ago, and a structurally mediocre one all the same. The Viterra combination (closed July 2, 2025) is the real deal: it turns Bunge into a Cargill/ADM-scale origination-to-processing-to-distribution network spanning both hemispheres, and management is capturing cost and network synergies “ahead of plan.” But scale in this industry buys survival and optionality, not pricing power. This is a spread business — you earn the crush margin and the merchandising basis the market hands you, and over a full cycle Bunge’s return on invested capital (6.7% reported, ~8% adjusted, TTM) barely clears its ~7.2% cost of equity. That is the signature of a good operator running hard inside a bad-economics industry, and no amount of “integrated global platform” language changes the arithmetic.

The tension is entirely about price and timing. The stock sits at ~$114, a few percent off its June-2026 all-time high of $131, having nearly doubled off its early-2025 low of ~$71. Its P/S and P/E now rank in the ~92nd–93rd percentile of their own decade-long history. Bulls will (correctly) point out that the trailing P/E is a trap — it’s calculated on trough GAAP earnings — and that on management’s freshly-raised 2026 guidance of $9.00–$9.50 adjusted EPS, the forward multiple is only ~12×, which is not demanding. The problem is why that guide jumped from $7.50–$8.00 to $9.00–$9.50 in the space of a single quarter: a favorable EPA biofuel (RVO) decision and a sharp, largely spot recovery in soy/softseed crush. Management itself describes the forward curves as “heavily inverted” with “limited visibility” into the second half. You are being asked to pay a full, near-record price for a deep cyclical whose earnings are being levered by biofuel policy that can move in either direction and by crush spreads that the capital cycle has always mean-reverted. The factor model agrees on what this is: a Value/oil-linked cyclical (Value beta 0.72, Energy/OilPrice loadings ~0.40) with a −77% lifetime maximum drawdown — a falling knife that has, for now, become a rising one.

Framing: a re-rated deep-cyclical value name riding a biofuel-and-scale narrative. Flip bullish on durable proof that Viterra synergies plus structural biofuel demand lift mid-cycle EPS to $10+ with ROIC sustainably above WACC. Flip bearish on an H2-2026 crush/biofuel disappointment or a policy reversal (US RVO, EU/Indonesia/Brazil mandates) that resets EPS toward $6–7 and exposes the all-time-high multiple. Tag: “You bought the whole ABCD at the top of the crush cycle.”

📈 Stock Price Action — Five-Year Event Map

Over five years Bunge has round-tripped from ~$68 (mid-2021) through a crush-super-cycle top, a two-year grind lower to a ~$71 trough (early 2025), and then a violent ~80% recovery to an all-time high of $131 (June 2026), closing recently at ~$114 — roughly 13% off the high, with a 52-week range of $71–$131. Today’s price sits near the top of the stock’s entire multi-year range, on earnings that management is guiding up quarter-to-quarter. The move is a FACT; the attributed drivers are INTERPRETATION.

Cycle narrative. (1–2) The 2021–2023 crush super-cycle — driven by the Ukraine war, tight global oilseed balances, and a renewable-diesel feedstock boom — produced record processing margins and pushed Bunge’s EPS to $14.88 in 2023; the stock, however, always traded at a low-single-digit-to-low-teens P/E on those “peak” earnings, so the price gains lagged the earnings and then faded as margins normalized. (3) By late 2024/early 2025, adjusted EPS had roughly halved and sentiment bottomed with the stock near $71, weighed down by biofuel-policy limbo and the multi-year regulatory slog to close Viterra. (4) The July 2, 2025 close of Viterra removed the overhang and began the re-rating. (5) The decisive leg was Dec-2025→Mar-2026: a clean Q4 (all four segments up year-over-year), the March 10 Investor Day laying out synergy and capital-return targets, and a favorable EPA Renewable Volume Obligation that re-lit the biofuel feedstock thesis. (6) The April 29 guidance raise to $9.00–$9.50 carried the stock to its $131 all-time high before a ~13% pullback on second-half visibility concerns and Middle-East-driven freight/energy disruption. Each of these price attributions is cross-referenced to the corresponding earnings print, 8-K, Investor Day, and policy event; none is a recommendation.

1. Executive Summary

Bunge Global SA is one of the four dominant global agricultural merchants and oilseed processors — the “ABCD” complex (ADM, Bunge, Cargill, (Louis) Dreyfus) — and, following its July 2025 combination with Viterra, arguably now the most geographically balanced origination-to-processing network of the group. The company buys, stores, transports, processes, and sells oilseeds (primarily soybeans, canola/rapeseed, sunflower) and grains (wheat, corn), converting oilseeds into vegetable oils (food and biofuel feedstock) and protein meal (animal feed), and operating milling and specialty-ingredient businesses on top. It is a physically enormous, capital-intensive, low-margin business: FY2025 revenue was $70.3 billion (including roughly six months of Viterra) on a gross margin of ~4.8% and an operating margin of ~1.8%.

The investment debate reduces to three questions, and this memo answers each directly. First, is there a moat? Only a weak one. Bunge sits inside a genuine scale-and-logistics oligopoly with very high barriers to entry (you cannot replicate a global elevator/port/crush network), but scale here confers cost advantage and optionality, not customer captivity or pricing power. Returns prove it: over the last full cycle ROIC has oscillated from ~14% at the 2021–23 peak to ~4% in 2025, averaging close to the cost of capital. This is Greenwald’s “economies of scale without customer captivity” — the oligopoly is durable, but its returns are not. Second, is the growth high-quality? The Viterra deal is transformative and the synergies look real and ahead of plan, but the underlying business is a mature, GDP-and-policy-linked spread earner, not a compounder; “growth” is mostly M&A-driven scale plus a biofuel-demand tailwind that is genuine but policy-dependent. Third, is the price right? No. The stock trades at an all-time high (~$114 vs. a $131 ATH), with P/S and P/E at ~92nd–93rd own-history percentiles, on 2026 earnings that management raised from $7.50–$8.00 to $9.00–$9.50 in a single quarter on the back of a biofuel-policy decision and a spot crush recovery. The forward P/E of ~12× is not egregious if $9+ proves to be the new mid-cycle — but the entire history of this industry argues that crush super-margins attract capacity and revert.

Capital allocation under CEO Greg Heckman and CFO John Neppl has been disciplined and shareholder-friendly: a decade of portfolio pruning (exiting sugar/bioenergy, corn milling), a large de-levering, and a new framework returning ~50% of discretionary cash flow to holders via a $2.80 dividend and a $2.7 billion buyback authorization. The balance sheet is solid (adjusted leverage 1.6×, readily-marketable inventories exceeding net debt). The bear case is not that Bunge is a bad company — it is a well-run one — but that a structurally ~cost-of-capital-return cyclical is being priced at the top of both its earnings cycle and its valuation range. No recommendation or price target appears below; the body evaluates embedded expectations and scenarios only.

2. Business Overview

Bunge’s purpose is prosaic and essential: it connects farmers who grow crops to the food, animal-feed, and fuel customers who consume them, capturing a spread at each step of the physical value chain — origination (buying grain/oilseeds from farmers and cooperatives), handling and storage (elevators), transportation and logistics (rail, truck, barge, ocean freight), processing (crushing oilseeds into oil and meal; milling wheat and corn), refining and specialty processing (turning crude vegetable oils into food-grade oils, shortenings, margarines, lecithin, and renewable-diesel feedstock), and merchandising/distribution (moving physical commodities and managing the associated price and basis risk).

Segments (post-Viterra, four reportable). Following the Viterra close and a 2025 reorganization, Bunge reports in four segments. FY2025 segment EBIT (with FY2024 / FY2023 for cycle context) was:

Two points jump out. First, the business is overwhelmingly an oilseed-crush company: Soybean plus Softseed processing/refining generated ~75% of FY2025 segment EBIT. The company’s fortunes rise and fall with the global “crush margin” — the spread between the cost of the oilseed and the combined value of the oil and meal it yields — and, increasingly, with the demand for vegetable oil as a renewable-diesel/biodiesel feedstock. Second, the FY2023 column ($2,222M soybean EBIT alone) shows how much higher segment earnings ran at the crush-cycle peak; 2024–25 is a normalization, and Corporate/Other EBIT of −$796M in 2025 reflects the heavy, one-time Viterra acquisition and integration costs distorting the GAAP picture.

Revenue model and recurring-ness. Revenue (~$70B) is almost entirely the physical throughput of commodities; it is “recurring” in the sense that the world eats and fuels every year, but it is emphatically not subscription-like or high-margin. Bunge makes money on volume × spread, and the spread is set by supply/demand, weather, trade flows, and policy — not by Bunge. The company mitigates flat-price risk by hedging (it does not speculate on outright commodity direction as a rule), so reported GAAP earnings are heavily distorted quarter-to-quarter by mark-to-market timing on those hedges (e.g., a −$1.28/share MtM swing in Q1-2026 alone), which is why management and the market focus on “adjusted” EPS. ~34,000 employees operate a global asset base of elevators, ports, crush plants, refineries, and mills across the Americas, Europe, Black Sea, and Asia-Pacific.

Verdict: An essential, physically vast, capital-intensive, low-margin commodity intermediary whose economics are dominated by the oilseed crush spread and, at the margin, by biofuel demand. Understandable business; unglamorous economics.

3. Industry Dynamics

The global agricultural merchandising and oilseed-processing industry is a classic scale oligopoly sitting on commodity economics. The “ABCD” traders — ADM, Bunge, Cargill, and Louis Dreyfus, joined increasingly by COFCO (China), Wilmar (Asia/palm), and Glencore Agriculture (now merged into Bunge as Viterra) — control the majority of the world’s cross-border grain and oilseed flows. Structurally, three features define the industry:

(1) Very high barriers to entry, low barriers to margin. Building a competitive origination-to-processing-to-distribution network requires tens of billions of dollars of elevators, ports, crush plants, rail/barge/ocean logistics, and decades of farmer and customer relationships. A new entrant essentially cannot appear — which is why the same handful of names have dominated for a century. But those barriers protect the existence of the oligopoly, not its returns: within the network, Bunge is a price-taker on both the input (farm-gate crop prices, set by global S&D) and the output (oil, meal, flour — all commodities). Barriers to entry ≠ pricing power. This is the crucial distinction the bull narrative blurs.

(2) Cyclicality driven by the crush spread and the capital cycle. Processing margins are set by the balance of oilseed supply (crop size, acreage, weather) against oil and meal demand (food, feed, biofuel). When margins spike — as in 2021–2023, when the Ukraine war, tight balances, and the renewable-diesel boom converged — the industry earns supernormal returns. Marathon’s capital-cycle framework then plays out with textbook reliability: high returns attract capital, the industry builds new crush capacity (the US alone added enormous soybean-crush capacity in 2023–2025 to feed renewable diesel), and the new supply compresses margins back toward mid-cycle. The 2024–2025 margin normalization is precisely this mechanism. The current 2026 re-acceleration is a policy-and-weather-driven counter-swing, not evidence the cycle has been repealed.

(3) Policy is a first-order driver, not a footnote. Biofuel mandates and tax policy (the US Renewable Volume Obligation and 45Z clean-fuel credit; EU renewable-energy directives; Indonesian and Brazilian biodiesel blending mandates) directly determine vegetable-oil demand and therefore crush margins. Trade policy (US–China soybean flows, Argentine export taxes, tariff regimes) reroutes global flows and creates or destroys arbitrage. Bunge’s own guidance raise in 2026 was explicitly attributed to a favorable EPA RVO decision. This makes the industry’s profit pool structurally volatile and politically exposed — a feature, not a bug, of investing here.

Profit pool and growth. The end-markets (food, feed, fuel) grow with population, protein consumption, and biofuel penetration — call it low-single-digit volume growth structurally, with biofuel providing an intermittent step-change in oil demand. It is a large, essential, slowly-growing profit pool that is shared among a stable oligopoly and reshuffled violently by weather, trade, and policy.

Verdict: a structurally okay-not-good industry. High barriers to entry and an essential product argue for durability; commodity price-taking, capital-cycle mean reversion, thin margins, and acute policy dependence cap the returns. It is a good industry to be the largest, lowest-cost survivor in — and a bad industry to expect sustained excess returns from.

4. Competitive Position

Name the moat. Bunge’s competitive advantage, to the extent it has one, is economies of scale in a network/logistics business — Greenwald’s third and strongest advantage type when paired with customer captivity, but here paired with none. Post-Viterra, Bunge operates one of the two or three largest global origination footprints (it describes itself as the largest agribusiness in Argentina, with expanded footprints in Canada, Australia, the Black Sea, and Brazil) feeding one of the largest crush-and-refining networks. The scale advantage is real and shows up in three ways:

• Origination density and optionality. The more elevators and ports you own across more origins, the more reliably you can source crop, arbitrage regional price differences, and keep your crush plants running at high utilization. Management’s most credible synergy claim from Viterra is exactly this: previously Viterra ran its elevators “purely through a merchandising lens,” and now the same network is optimized against Bunge’s global processing system — “keeping our processing and refining plants running at high capacities” and capturing margin “through improved logistics and better coordination.” That is a genuine, durable, scale-driven efficiency.
• Global balance / diversification. With both hemispheres, multiple oilseeds (soy, canola, sun), and origination-plus-destination value chains, Bunge can shift where it processes and merchandises to wherever the margin is — the Q1-2026 result, where soy/softseed strength offset a weak grain-merchandising/freight quarter, is the intended proof of concept. Diversification dampens (does not eliminate) the cyclicality.
• Cost position. As one of the largest processors, Bunge should sit low on the industry cost curve, which is what lets an ~cost-of-capital business survive the troughs that would kill a subscale operator.

What the moat is NOT. It does not produce pricing power (customers buy a commodity and switch on price/reliability), it does not produce customer captivity (no switching costs, no lock-in, minimal brand — even the branded consumer oils are low-margin), and it does not produce durably high returns. The definitive test: apply the “moat must show up in a financial outcome that would deteriorate without it” standard. Bunge’s ROIC ranged from ~14% (2021, 2023) to ~4% (2025) — a >3× swing driven entirely by exogenous crush margins, not by any Bunge-specific advantage eroding or strengthening. A true moat produces stable excess returns; Bunge’s returns are a levered play on an external spread. The scale advantage keeps Bunge in the game as a low-cost survivor; it does not confer the pricing power that would make it a compounder.

Direct comparison vs. peers. ADM (the closest public comp; FactorsToday factor-similarity 0.87) is the same animal — a scaled oilseed processor/merchant with a larger nutrition/ingredients arm, currently working through an accounting/segment-reporting controversy. Cargill (private) and Louis Dreyfus (private) are Bunge’s true scale peers; Wilmar dominates Asian palm; COFCO is the Chinese state champion. Against this set, post-Viterra Bunge is now clearly a top-tier player by origination footprint and oilseed-crush capacity — the combination was pursued precisely to reach ADM/Cargill scale. But “we are now as big as the other giants in a commodity oligopoly” is a statement about survival and optionality, not about excess returns.

Verdict: a strengthened but shallow moat. Bunge has a real, wide-and-durable cost-and-scale advantage that guarantees it a seat at the table as one of the last survivors — and essentially no pricing/captivity moat that would let it earn sustained returns above its cost of capital. Crowded is the wrong word for a four-firm oligopoly; “structurally low-return” is the right one.

5. Growth History and Forward Opportunities

History: cyclical, not secular. Bunge’s revenue over five years — $41.4B (2020) → $59.2B (2021) → $67.2B (2022) → $59.5B (2023) → $53.1B (2024) → $70.3B (2025) — is dominated by commodity price swings and, in 2025, the Viterra consolidation, not by underlying volume compounding. Earnings tell the cyclical story more cleanly: GAAP diluted EPS ran $7.41 (2020) → $13.45 (2021) → $10.52 (2022) → $14.88 (2023, the crush-cycle peak) → $7.99 (2024) → $4.91 (2025, trough + heavy Viterra costs and MtM). ROE swung from 25% (2021) to 6% (2025). There is no secular growth trend in this series — there is a super-cycle that peaked in 2021–2023 and a normalization since, now interrupted by a 2026 policy-and-crush upswing.

Forward opportunities — three, in descending quality:

1. Viterra integration and synergies (highest-quality, self-help). This is the most credible and controllable driver. Management reports Viterra cost synergies “running ahead of plan” and has “identified significant network and commercial opportunities” beyond the initial cost target. The original deal thesis targeted meaningful annual run-rate synergies (cost plus network/commercial) building over several years. Because these are self-help and network-driven (utilization, logistics optimization, procurement), they are the closest thing Bunge has to non-cyclical earnings growth. The risk is integration complexity and the temptation to count cyclical crush strength as “synergy.”

2. Biofuel / renewable-diesel feedstock demand (real but policy-levered). The structural shift toward renewable diesel, sustainable aviation fuel, and higher biodiesel blend mandates (US RVO, Brazil, Indonesia, EU) is a genuine multi-year tailwind for vegetable-oil demand — and Bunge, as a leading oil producer with the Bunge–Chevron renewable-feedstock JV, is well positioned. Management sees US soybean-oil inventories drawing down through H2-2026 as the RVO takes effect. But this driver is only as durable as the policy behind it: the same call flagged “limited visibility” and “heavily inverted” forward curves, and biofuel mandates are perennial political footballs.

3. Organic growth capex and bolt-ons (steady, modest). Bunge is spending $1.5–1.7B/year on capex, including greenfield/expansion projects (e.g., the Avondale, Louisiana multi-oil refining facility) and completed the ~$105M+ acquisition of IFF’s soy-protein/lecithin business in March 2026 to build out specialty/food ingredients — a deliberate, sensible tilt toward higher-margin, less-cyclical value-added products. These improve mix at the margin but do not change the company’s fundamental character.

Verdict: mostly low-quality (cyclical/M&A/policy) growth with one high-quality kernel (Viterra self-help synergies). The honest characterization is a mature spread business whose forward earnings growth depends primarily on (a) executing Viterra synergies and (b) the direction of the crush cycle and biofuel policy — one of which Bunge controls and two of which it does not.

6. Financial Quality

Margins are structurally razor-thin and cyclical. FY2025 gross margin was 4.8%, operating margin 1.8%, net margin 1.2% — and these are normal for the industry, not a problem to be fixed. The relevant “margin” is the crush spread, which is exogenous. EBITDA margin ran 2.8% (2025), 3.9% (2024), 6.0% (2023 peak). Because margins are thin, small moves in the spread produce large swings in profit — operating leverage cuts both ways violently.

Returns on capital hover around the cost of capital — the central financial fact. Reported ROIC (per management, TTM at Q1-2026) was 6.7%, or ~8% adjusted for construction-in-progress and excess cash; ROE was 6.3% in 2025. Management’s own stated cost of equity is 7.2%. So on a trailing basis the business is earning roughly its cost of capital — and that is at a below-mid-cycle point burdened by Viterra costs. At the 2021/2023 peak, ROIC reached ~14%; averaged across the cycle, Bunge earns modestly above its cost of debt and around its cost of equity. This is the number that defines the thesis: a business that, through the cycle, roughly breaks even against its cost of capital is not a value compounder — it is a spread earner whose intrinsic value grows slowly and lumpily. Management’s framing — “cash return on equity of 9.1% vs. cost of equity of 7.2%” — is the most favorable honest cut, and even it implies only a ~2-point spread at a recovering point in the cycle.

Cash flow is lumpy and working-capital-dominated. Because Bunge finances enormous inventories and receivables, operating cash flow is dominated by working-capital swings driven by commodity prices and volumes — it was deeply negative in high-price years (−$5.5B in 2022, −$2.9B in 2021 as inventories/receivables ballooned) and strongly positive when prices fell (+$3.3B in 2023). This is normal for a merchant and is why the company emphasizes readily-marketable inventories (RMI) — highly liquid, hedged, near-cash commodity inventories — as an offset to debt. At Q1-2026, RMI exceeded net debt by ~$400M, and “adjusted net debt” (net of RMI) is the metric on which leverage is managed (1.6× adjusted leverage). GAAP free cash flow figures for this business are close to meaningless in isolation; the “adjusted funds from operations” ($1.7B in 2025) and “discretionary cash flow” ($1.25B in 2025, ~$1.35B TTM at Q1-26) are the operative measures.

Balance sheet: solid and de-levered. FY2025: total assets $44.5B, total debt ~$15.9B, cash $1.1B, net debt ~$13.1B, total equity $17.4B (incl. $1.5B minority). The debt jumped from ~$7B (2024) because Bunge assumed/issued acquisition debt for Viterra, but adjusted leverage of 1.6× (Q1-26), ~$9.7B of undrawn committed facilities, an unused $3B commercial-paper program, and RMI-covered net debt make this a comfortably-financed balance sheet. A credit-rating upgrade accompanied the combination. One quality caveat: post-Viterra, goodwill ($3.1B) plus intangibles ($3.45B) total ~$6.6B, so tangible book equity is only ~$9.3B (~$47/share) against a ~$114 price — a P/TBV of ~2.4×, materially richer than the ~1× P/TBV at which this stock historically traded, and a reminder that the “cheap on book” argument has weakened.

Quality of earnings. Two persistent distortions: (1) MtM hedge timing makes GAAP quarterly EPS nearly unusable (GAAP Q1-26 EPS was $0.35 vs. $1.83 adjusted — a $1.28 MtM swing); adjusted EPS is the right lens but requires trusting management’s add-backs. (2) Notable/one-time items — Viterra transaction and integration costs, a US pension-plan settlement, an investment impairment, and divestiture gains (Sugar & Bioenergy JV sold 2024; corn milling divested 2025) — heavily distort both GAAP and year-over-year comparisons through 2024–2025. The add-backs appear reasonable and consistently applied, but the sheer volume of adjustments right now (a mega-merger year) means QoE is temporarily murky.

Verdict: high-quality balance sheet, low-quality economics. The financials do NOT improve durably with scale in the way a real moat would produce — margins and returns are set by the crush spread, and ROIC ≈ WACC through the cycle. Scale buys survival, liquidity, and optionality, not economic rents. The one genuinely favorable trend is the Viterra-driven step-up in scale and the de-levering discipline.

7. Capital Allocation

Capital allocation under Greg Heckman (CEO since 2019) and John Neppl (CFO) has been the brightest part of the Bunge story, and it deserves credit. The Heckman-era playbook has been: simplify the portfolio, fix the operating model, de-lever, and then use scale to consolidate.

Portfolio pruning (good). Bunge exited or divested lower-return, more-volatile businesses — the Brazilian sugar & bioenergy JV (sold to BP, 2024), corn milling (divested 2025), and various non-core assets (~$1.2B of divestiture proceeds in 2025) — sharpening the company around oilseed processing, refining, and grain merchandising. This is textbook good capital allocation: shrinking the bad to strengthen the core.

The Viterra combination (transformative, price-disciplined-ish). The July 2025 stock-and-cash acquisition of Viterra (from Glencore, the Canada Pension Plan Investment Board, and others) is the defining capital-allocation act — a bet that scale and geographic balance are worth more than the diversification of staying smaller. Consideration was a mix of ~$2 billion cash plus a large issuance of Bunge shares (which is why weighted-average diluted shares rose from ~142M in 2024 toward ~166M for 2025 and ~197M currently). The dilution is significant, but the strategic logic — reaching Cargill/ADM scale, adding Black Sea/Australian/Canadian origination, and unlocking network synergies — is sound, and management pre-funded much of the dilution with buybacks. Integration is reportedly ahead of plan on cost synergies. The risk: overpaying for scale in a low-return industry, and the classic hazard of a merger of two low-ROIC businesses producing a bigger low-ROIC business. It is too early to score the deal on returns; the operating integration signs are encouraging.

Shareholder returns (disciplined framework). At the March 2026 Investor Day, management adopted a framework targeting ~50% of discretionary cash flow returned to shareholders. The mechanics: a dividend of $2.80/share in 2025 ($0.70/quarter, raised from $0.68) — ~2.5% yield at $114 — and a $2.7 billion cumulative buyback authorization under which 26.4M shares had been repurchased for $2.5B (with ~$249M remaining, expected to complete in 2026). Notably, a chunk of the buyback was explicitly a Viterra-dilution offset. The discipline caveat management itself flagged on the Q1-26 call: leverage is currently “a little elevated with Moody’s versus where we want to be,” so incremental buyback capacity in 2026 is constrained by the de-levering priority — a sensible ordering.

Incentive alignment. Compensation is tied to adjusted EPS, ROIC/return metrics, and cash flow — appropriate for this business, and the focus on adjusted ROIC vs. cost of capital in every earnings deck signals that management understands the central issue (returns above WACC) even as the business struggles to durably clear it. Insider activity (per the Form 4 corpus) is dominated by routine grants/vesting and 10b5-1 dispositions rather than large discretionary open-market purchases — i.e., no strong insider conviction buy signal, but no alarming discretionary selling either; typical for a large-cap.

Verdict: management has allocated capital intelligently — pruning weak businesses, de-levering, executing a strategically-coherent (if dilutive) transformative deal, and returning cash on a disciplined framework. This is a well-run company. The limitation is not the allocator; it is the canvas — even excellent capital allocation inside a ~cost-of-capital-return industry produces good-not-great shareholder value compounding.

8. Changes and Headwinds — Last Two Years

Strategic / structural changes:

• Viterra combination closed July 2, 2025 — the transformative event; a new four-segment reporting structure; ~$70B pro-forma revenue; a step-change in origination scale and geographic balance; a credit-rating upgrade and a re-levered-then-de-levering balance sheet.
• Portfolio reshaping — Sugar & Bioenergy JV sold (2024), corn milling divested (2025), IFF soy-protein/lecithin business acquired (March 2026) — a deliberate tilt toward oilseeds and value-added ingredients.
• March 10, 2026 Investor Day — new long-term outlook, synergy roadmap, and the ~50%-of-DCF capital-return framework; a key catalyst for the stock’s re-rating.
• Redomiciliation to Switzerland (Bunge Global SA, effective November 2023) from Bermuda — a structural/tax change; the entity now files under a new CIK.

Operating / market changes and headwinds:

• Crush-margin normalization (2024–2025) then a 2026 recovery — the dominant earnings driver, now swinging back up on biofuel policy and strong global soybean-meal demand.
• Biofuel-policy whipsaw — the favorable EPA RVO decision (2026) was a major positive; but the delay of certain provisions (e.g., the half-RIN restriction to 2028) and perennial policy uncertainty keep this a two-way risk. Brazil, Indonesia, and EU mandates add further swing factors.
• Geopolitical / trade disruption — the 2026 Middle-East conflict spiked bunker-fuel/ocean-freight costs (hurting the Grain Merchandising & Milling and ocean-freight results in Q1-26) and disrupted trade flows; US–China soybean trade remains unresolved, a potential swing factor for soy flows; Argentine export-tax and Black Sea dynamics persist.
• Weather / crop risk — two consecutive poor European sunflower crops pressured softseed margins; El Niño risk for the 2026/27 season is an emerging watch item.

Verdict: On balance these changes strengthen the franchise’s scale and resilience (Viterra, portfolio focus, de-levering) while increasing exposure to policy and geopolitical volatility (biofuel, trade, freight). The net effect on the thesis is neutral-to-slightly-positive on business quality and clearly negative on predictability — a bigger, better-balanced, but still policy-and-cycle-whipsawed earner.

9. Risk Analysis (Risk Matrix)

The dominant risks are all variations on one theme: you are buying a policy-and-cycle-levered spread business at the top of its earnings and valuation range. Catastrophic loss is unlikely (investment-grade, hedged, essential-goods, RMI-covered); the real risk is a multi-year de-rating and earnings normalization from here.

10. Valuation Discussion (Embedded Expectations)

No price target and no recommendation follow — only what the current price embeds. At ~$114, with ~197M shares, Bunge carries a market capitalization of ~$22.4B and, adding ~$13.1B net debt and ~$1.5B minority interest, an enterprise value of ~$37B.

The trailing multiples are a cyclical trap; the forward multiples are the real anchor. On trailing GAAP EPS ($4.91 for 2025, or ~$4.30 TTM), the P/E is ~23–26× — which the AZI own-history percentile engine flags at the 92nd percentile (P/S at the 93rd, composite 83rd). Read naïvely, that screams “most expensive ever.” But this is the classic cyclical distortion: the P/E is high because E is at a trough (2025 was depressed by Viterra costs, MtM, and normalized crush). The honest anchor is the forward multiple on management’s raised 2026 guidance of $9.00–$9.50 adjusted EPS, which puts the stock at ~12× forward earnings — squarely in the middle of Bunge’s historical 6–13× range and not, on its face, expensive.

So the entire valuation question collapses to one judgment: is ~$9 the new mid-cycle, or a policy-and-crush peak? Three scenarios:

• Bear (~$6.00–6.50 normalized EPS). Biofuel tailwinds fade or reverse; crush margins mean-revert as new capacity bites; Viterra synergies are partly offset by integration friction. On a ~10–11× multiple (a de-rating back toward the historical average, appropriate for a cyclical printing normalized numbers), this frames a value zone well below the current price. The −77% lifetime max drawdown is the reminder that this scenario is not academic.
• Base (~$8.00 mid-cycle EPS). 2026’s $9+ proves modestly above mid-cycle; Viterra synergies add a durable ~$1–1.5/share of self-help; biofuel provides a structural (if choppy) demand floor. At ~11–12×, the base case roughly supports today’s price — i.e., the stock is close to fairly valued if the business has genuinely re-based higher on scale + biofuel, with limited margin of safety.
• Bull (~$10.00+ mid-cycle EPS). Viterra network/commercial synergies exceed the initial cost target; biofuel demand structurally tightens vegetable-oil balances (RD/SAF ramp); crush stays elevated. At ~12–13×, this supports a meaningfully higher price and would retroactively justify the re-rating.

What the market is underwriting. At ~$114 on ~12× the 2026 guide, the market is pricing Bunge as though $9+ is close to sustainable and the Viterra deal has durably lifted the earnings base — i.e., it is giving the company credit for the bull-to-base outcome now, at an all-time-high price, before the H2-2026 crush and biofuel policy have played out and before the synergies have been proven through a full cycle. The market is correctly ignoring the misleading trailing P/E; it is arguably incorrectly extrapolating a spot/policy-driven earnings spike into a permanent mid-cycle. On an EV/EBITDA basis (~9× the ~$4B of implied 2026 EBITDA), the valuation is reasonable for a scaled trader — but “reasonable at peak-cycle EBITDA” is exactly how cyclicals top.

Cross-checks. P/TBV of ~2.4× is well above the stock’s historical ~1× (a warning that the “trades below/around book” safety net has thinned post-Viterra goodwill). P/B of ~1.4× (63rd own-history percentile) is elevated but not extreme. The ~2.5% dividend yield and ~50%-of-DCF return framework provide a modest support. Against peer ADM (same economics, ~similar mid-cycle multiples, but currently under an accounting cloud), Bunge trades at a deserved relative premium for its cleaner story and superior execution.

Valuation verdict: the stock is not cheap and not egregiously expensive — it is a fair-to-full price for a business at a favorable point in its cycle. The embedded expectation is that $9+ EPS is roughly the new normal; the risk is that it is a peak. There is little margin of safety at the all-time high.

11. Variant Perception

Consensus view. The Street has warmed sharply to Bunge in 2026: the Viterra deal is seen as strategically transformative, synergies are running ahead of plan, the biofuel setup is favorable, and management raised guidance twice — analysts on the Q1-26 call were effusive (“congrats on the very strong quarter”; praise for the Investor Day). Consensus is that Bunge is a scaled, well-run, de-levered agribusiness re-rating toward its rightful place alongside ADM/Cargill, with $9+ earnings power and a shareholder-return story.

Strongest bull case. Viterra genuinely transforms the earnings algorithm: (1) durable, self-help cost + network synergies add $1–2/share of non-cyclical earnings; (2) the renewable-diesel/SAF demand ramp structurally tightens global vegetable-oil balances for years, keeping crush margins elevated; (3) the combined footprint’s diversification dampens the historical cyclicality (as Q1-26 demonstrated), warranting a higher, less-cyclical multiple; (4) disciplined ~50%-of-DCF capital return compounds per-share value. In this world, $9+ is mid-cycle, ROIC durably clears WACC, and the stock is early in a multi-year re-rating.

Strongest bear case. Bunge is a ~cost-of-capital-return commodity spread business (ROIC 6.7%, adj 8%, vs. 7.2% CoE) being valued at an all-time-high price on peak-of-cycle, policy-juiced earnings. The 2026 guide jumped from $7.50 to $9+ in one quarter on a biofuel decision and a spot crush recovery that management admits has “limited visibility” and “heavily inverted” forward curves. The capital cycle guarantees new crush capacity chases the current margins and reverts them; biofuel policy can reverse; two low-ROIC businesses combined is still low-ROIC. When 2027 EPS normalizes toward $6–7, the ~12× forward multiple applied to a lower number — plus a de-rating — takes the stock materially lower. P/TBV of ~2.4× and P/S at the 93rd percentile show the safety net has thinned.

The 3–5 assumptions that matter most:

1. Is $9+ mid-cycle or peak? (The whole thesis.) Falsified bearishly by an H2-2026 crush/biofuel disappointment; confirmed bullishly by 2027 guidance holding ≥$8.5 in a normal crop year.
2. Are Viterra synergies durable and additive to mid-cycle, or a cover for cyclical strength? Falsified by synergy slippage or margins not reaching the Investor Day targets; confirmed by explicit synergy-capture disclosure tracking ahead.
3. Does the renewable-diesel/biofuel demand ramp structurally tighten oil balances, or does policy whipsaw dominate? Falsified by an RVO/45Z/EU reversal; confirmed by sustained mandate-driven feedstock demand and drawing inventories.
4. Has diversification genuinely lowered the cyclicality (justifying a higher multiple)? Falsified by a sharp full-company earnings drawdown; confirmed by earnings resilience through a weak-crush year.
5. Does ROIC sustainably exceed WACC post-Viterra? Falsified by ROIC stuck ≤7–8%; confirmed by a durable move to double digits.

Factor-positioning read (from the tape and factor model). The empirical picture reinforces the bear framing of what kind of stock this is: FactorsToday loads Bunge as a Value stock (Value beta 0.72) with meaningful Energy-sector (0.40) and OilPrice (0.38) exposure — i.e., the market is treating BG as an oil-linked value cyclical, not a defensive staples compounder. Its lifetime maximum drawdown is −77% and its long-run Sharpe is poor (~0.14), the fingerprint of a deep cyclical. The recent tape shows a one-year total return of ~+54% (a powerful cyclical-recovery run) that has just rolled over (m3 return negative, ~13% off the ATH) — consistent with a stock that has run hard on a narrative and is now digesting. The factor-similar peer set (ADM, NTR, oil-refiner and ethanol names) confirms the market files Bunge with commodity processors, not compounders. Interpretation (regime-caveated): consensus may be offsides in extrapolating a policy-and-crush-driven earnings spike into a permanent re-rating; the positioning is that of a crowded cyclical-recovery trade near its high, not a durable-growth story — evidence for where the variant perception (peak-cycle mispricing) may prove correct, not a price call.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the explicit, quantified Viterra synergy target (cost vs. network/commercial), and what is the run-rate captured to date? (Investor Day set a roadmap; tracking the hard number is essential to separating self-help from cycle.)
2. What does management consider “mid-cycle” adjusted EPS for the combined company in a normal crush and biofuel-policy environment — $7.5, $8, or $9?
3. How much of 2026’s guided $9+ is biofuel-policy-dependent and would reverse under an RVO/45Z rollback?
4. What is the pro-forma, full-year (not half-year) Viterra revenue and EBIT contribution, and how do the combined 2025 pro-forma segment margins compare to standalone Bunge?
5. What is the durable share count after the remaining ~$249M buyback and any future dilution offset — and what is the true weighted-average diluted figure now (~197M)?
6. How will the leverage-vs-buyback tension resolve given Moody’s is watching leverage — does capital return get throttled if the cycle turns down?
7. What is the sustainable ROIC target management believes the combined company can earn through the cycle, and by when?

14. What Must Be True (Bull and Bear, each with a falsification test)

For the BULL case to be right, the following must be true:

• Viterra durably re-bases earnings power higher. Cost + network synergies must deliver a structural, non-cyclical uplift such that mid-cycle adjusted EPS is ≥$8.5–9 and ROIC sustainably clears WACC (>8–9%). — Falsification test: if 2027 adjusted EPS guidance is set below ~$7.5 in a normal crop year, or if adjusted ROIC remains stuck at ≤7–8% two years post-close, the re-basing thesis is broken.
• Biofuel demand is a structural (not merely policy-cyclical) tailwind that keeps vegetable-oil balances tight. — Falsification test: a US RVO/45Z reversal or EU/Indonesia/Brazil mandate cut that visibly loosens oil S&D and compresses crush.
• Diversification has genuinely lowered cyclicality, justifying a higher, less-volatile multiple. — Falsification test: a >30% year-over-year decline in full-company adjusted EBIT in the next weak-crush year.

For the BEAR case to be right, the following must be true:

• $9+ 2026 EPS is a policy-and-cycle peak, and normalized EPS reverts toward $6–7 as crush capacity additions and biofuel-policy normalization bite. — Falsification test: if crush margins and adjusted EPS hold ≥$8.5 through 2027 despite the well-flagged capacity additions and a normal crop, the “peak-earnings” claim fails.
• The business remains a ~cost-of-capital-return spread earner whose scale buys survival, not rents. — Falsification test: a durable multi-year move in through-cycle ROIC into double digits would refute it.
• The all-time-high valuation de-rates as earnings normalize. — Falsification test: the multiple holding ≥12× forward and the price holding near highs through a full crush-margin down-leg.

The analysis in the numbered sections above is written to be position-free and carries no price target or buy/sell recommendation. The single, clearly-labeled exception is the opinion block at the top. The Source Appendix follows.

APPENDIX A — Standard Diligence Questionnaire

Bunge Global SA (NYSE: BG) — as of July 10, 2026

Supplemental to the research memo. Fact / Interpretation / Assumption labels applied where material.

General

What thoughtful questions have other investors asked about this company? The recurring, sophisticated questions (evident on recent calls): (1) How much of the 2026 guidance raise is real vs. biofuel-policy timing? — analysts probed why the guide jumped from $7.50–8.00 to $9.00–9.50 and why H2 visibility is “limited” despite the RVO; (2) Earnings cadence — the H1/H2 split moved from 30/70 to 40/60 as Q1 surprised, and investors want to know normalized seasonality post-Viterra; (3) Buyback pace vs. de-levering — whether Bunge pulls forward buybacks or prioritizes getting leverage back in Moody’s comfort zone; (4) Viterra synergy quantification — separating self-help from cyclical crush; (5) Crush-curve inversion — why forward curves are so inverted and what it signals about H2. These are the right questions; they all circle the same issue — is this peak or plateau.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Recovering toward a cyclical high. 2025 (GAAP EPS $4.91, ROE 6.3%) was a trough burdened by Viterra costs/MtM; 2026 guidance of $9.00–9.50 adjusted is a sharp recovery driven by biofuel policy and a spot crush upswing — likely above mid-cycle, not below. The 2023 peak was $14.88 GAAP EPS / 20% ROE.

Driven by external environment or internal actions? Both, but external dominates: crush margins and biofuel policy (external) set the level; Viterra synergies, portfolio pruning, and de-levering (internal) are the controllable overlay. Interpretation: ~70–80% external.

How stable are revenues? Unstable in dollar terms (commodity-price-driven: $41B→$70B range over five years) but stable in the sense that global food/feed/fuel demand is non-discretionary. Volumes are far more stable than revenue dollars or margins.

Outlook for products/services? Structural low-single-digit volume growth in food/feed; a genuine multi-year (but policy-levered) tailwind in vegetable oil for renewable diesel/SAF. Fact: management sees US soy-oil inventories drawing down through H2-2026 on the RVO.

How big is this market — growing, shrinking, domestic or international? Enormous and global — Bunge operates across the Americas, Europe, Black Sea, and Asia-Pacific; the global oilseed/grain trade is measured in hundreds of millions of tonnes. Growing slowly with population/protein/biofuel.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Interpretation: Structurally stable (a durable four-firm-plus oligopoly), but margin competition intensifies when crush capacity is added — the current capital-cycle build in US soy crush will pressure margins. Consolidation (Bunge–Viterra) slightly reduces the number of independent giants.

How profitable is the business (ROIC, ROE)? Fact: Low and cyclical. TTM ROIC 6.7% (adj ~8%) vs. ~7.2% cost of equity; ROE 6.3% (2025), having been 20–25% at the 2021/2023 peak. Through-cycle, roughly at the cost of capital.

How profitable is the industry — how many competitors, what barriers to entry? Very high barriers to entry (global asset networks costing tens of billions; decades of relationships) but low barriers to margin (commodity price-taking). A handful of dominant players (ADM, Bunge, Cargill, LDC, Wilmar, COFCO). Barriers protect the oligopoly’s existence, not its returns.

Can the business be easily understood? Yes at a high level (buy crop, process, sell oil+meal, capture the spread); no at the quarter-to-quarter level (MtM hedge timing makes GAAP EPS nearly unusable — Q1-26 GAAP $0.35 vs. adjusted $1.83).

Can it be undermined by foreign low-cost labor? No — it is capital/asset/logistics-intensive, not labor-intensive; the competitive axis is scale and network, not labor cost.

Do brands matter? Minimally. Some branded consumer oils exist, but the business is overwhelmingly B2B commodity/ingredient supply; brand is not a moat here.

Nature of competition / customers’ switching costs? Competition is on price, reliability, geographic reach, and execution. Switching costs are low — customers (food, feed, fuel producers) buy commodities and multi-source. Bunge’s edge is reliability of supply from a dense global network, not lock-in.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Interpretation: The origination/logistics network’s optionality value and the Viterra synergy potential are not on the balance sheet; conversely, post-Viterra goodwill+intangibles (~$6.6B) inflate book relative to tangible book.

Off-balance-sheet liabilities? Standard for a merchant: operating leases, purchase commitments, guarantees, and derivative positions (largely hedges). Nothing unusual flagged; RMI-based leverage management is disclosed.

How conservative is the accounting? Interpretation: Reasonable but currently opaque due to merger-year noise. Heavy reliance on non-GAAP “adjusted” measures (MtM timing, notable items) is necessary for this business but requires trusting management’s add-backs; they appear consistently applied.

How CapEx-hungry is the business? Moderately: $1.5–1.7B/year (2026 guide) on a ~$44B asset base, including growth greenfields (e.g., Avondale, LA refining) and sustaining capex (~$485M in 2025). Not as capital-light as branded consumer, not as heavy as pure heavy industry.

Capital Allocation & Management

How much FCF does the business generate, how is it used, what is the philosophy? Fact: GAAP FCF is lumpy/working-capital-dominated; the operative measures are adjusted funds from operations (~$1.7B, 2025) and discretionary cash flow (~$1.25B, 2025; ~$1.35B TTM). Philosophy (Investor Day, March 2026): ~50% of discretionary cash flow returned to shareholders, balance to growth capex/M&A, with de-levering currently prioritized.

Significant acquisitions recently? Yes — the transformative Viterra combination (July 2, 2025, ~$2B cash + large share issuance) and the smaller IFF soy-protein/lecithin acquisition (March 2026, ~$105M+). Also active divestitures (Sugar & Bioenergy JV 2024; corn milling 2025).

Buying back shares? Yes — $2.7B cumulative authorization; 26.4M shares repurchased for $2.5B, ~$249M remaining (to complete 2026); $551M repurchased in 2025. A portion explicitly offsets Viterra dilution.

Issuing large amounts of new shares to insiders? No unusual insider issuance; the large 2025 share issuance was deal consideration to Viterra/Glencore holders (diluted share count ~142M→~197M). SBC is modest (~$73M in 2025).

Compensation policy of directors/management? Interpretation: Tied to adjusted EPS, ROIC/return metrics, and cash flow — appropriate; management explicitly benchmarks adjusted ROIC vs. cost of capital in every deck.

Motivations of management? Interpretation: Heckman/Neppl have executed a credible multi-year turnaround (portfolio focus, de-levering, the Viterra deal); incentives appear aligned with per-share value and returns-above-WACC. No red flags in insider behavior (routine grants/10b5-1, no alarming discretionary selling, no strong conviction buying either).

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? No — Bunge Global SA is a Switzerland-domiciled company whose registered shares trade directly on the NYSE as common equity (ordinary “registered shares”). Not an ADR, not an MLP, no K-1. Note: as a non-US-incorporated issuer, dividend withholding/tax treatment should be confirmed by the holder, but it files as a domestic-style filer (10-K/10-Q).

Dividend policy? Fact: $2.80/share annualized ($0.70/quarter, raised from $0.68 in 2025); ~2.5% yield at $114; payout ~50% of discretionary cash flow under the new framework.

How profitable is the business? Low-margin, cyclical (see above): ~1.8% operating margin, ROIC ≈ WACC through cycle.

Is net income diverging from cash from operations? Frequently and by design — working-capital swings make OCF diverge sharply from NI (OCF was −$5.5B in 2022 vs. +$1.6B NI; +$3.3B in 2023 vs. +$2.2B NI). This is normal merchant behavior, not a quality flag — but it makes any single-year FCF number unreliable.

Risks & Downside

What factors would cause the stock to decline? A crush-margin/biofuel-policy reversal dropping EPS back toward $6–7; a Viterra integration stumble; a multiple de-rating from all-time-high levels; a working-capital/liquidity shock in a price spike; trade/geopolitical disruption.

Risk of a catastrophic loss? Interpretation: Low. Investment-grade, hedged, diversified, essential-goods, RMI-covered net debt, $9.7B undrawn facilities. A permanent-impairment scenario would require a simultaneous liquidity crisis and prolonged negative-margin environment — remote.

Chance of a total loss? Very low. The primary risk is a multi-year de-rating and earnings normalization (a 30–50% drawdown is historically plausible — lifetime max drawdown −77%), not a wipeout.

Recent News & Events

Has the business environment changed recently? Yes, materially: the Viterra close (July 2025), the favorable EPA RVO biofuel decision (2026), the March 2026 Investor Day, and the 2026 Middle-East conflict (spiking freight/bunker costs, disrupting flows). Note: a news-service feed returned no scored articles for BG at pull time; the recent-events read was built from the company’s filings and transcripts and public/industry sources.

Significant acquisitions? Viterra (2025) and IFF soy protein (2026) — see above.

Change in accounting policies? No policy change flagged, but a new four-segment reporting structure post-Viterra and heavy merger-related notable items make year-over-year comparisons difficult. Redomiciled to Switzerland (Bunge Global SA) in November 2023, changing the filing entity/CIK.

Recent changes — new markets, facilities, management? New/expanded origination in Black Sea, Australia, Canada, and enlarged Argentina/Brazil footprints via Viterra; greenfield refining (Avondale, LA); IFF specialty-ingredients addition; stable Heckman/Neppl leadership.

APPENDIX B — Source Appendix

Bunge Global SA (NYSE: BG) — Research as of July 10, 2026

Primary sources prioritized over secondary. Every non-obvious fact in the memo traces to an entry below . Facts are labeled in the body as Fact / Interpretation / Assumption / Open Question.

Primary — SEC filings (US filer; CIK 0001996862)

The trailing 60-month SEC corpus (3× 10-K, 7× 10-Q, 53× 8-K, DEF 14A/PRE 14A, S-4 Viterra registration, Form 3/4/5, plus 11-K/S-8). Key documents relied on:

1. Form 10-K, FY2025 (filed 2026-02-19; bg-20251231.htm) — Viterra combination disclosure (closed July 2, 2025), four-segment reporting and segment EBIT (Soybean $1,225M / Softseed $521M / Other Oilseeds $118M / Grain Merch & Milling $465M; Total Segment EBIT $2,329M; Corporate & Other −$796M), revenue $70.3B, GAAP diluted EPS $4.91 (vs $7.99 FY2024), dividend $2.80/share, $2.7B buyback authorization (26.4M shares / $2.5B repurchased, ~$249M remaining), ~34,000 employees, goodwill/intangibles from Viterra, Avondale (LA) refining facility.
   • URL: https://www.sec.gov/Archives/edgar/data/1996862/000162828026009842/bg-20251231.htm
2. Form 10-K, FY2024 (filed 2025-02-20; bg-20241231.htm) — standalone pre-Viterra baseline; FY2024 financials.
   • URL: https://www.sec.gov/Archives/edgar/data/1996862/000199686225000008/bg-20241231.htm
3. Form 10-K, FY2023 (filed 2024-02-22; bg-20231231.htm) — crush-cycle-peak year (EPS $14.88, ROE 20%).
4. Form 10-Q, Q1 2026 (filed 2026-04-29; bg-20260331.htm) — latest quarterly financials.
   • URL: https://www.sec.gov/Archives/edgar/data/1996862/000162828026028235/bg-20260331.htm
5. Forms 10-Q Q2/Q3 2025 and prior (mirrored) — quarterly cadence and Viterra consolidation onset.
6. Form S-4 (Viterra acquisition registration statement) — deal structure/consideration.
7. DEF 14A / PRE 14A proxy statements — compensation structure (adjusted EPS / ROIC / cash-flow metrics), board.
8. Forms 3/4/5 (insider transactions corpus) — routine grants/vesting/10b5-1 dispositions; no large discretionary open-market purchases.

Primary — Earnings-call transcripts (via ROIC.ai; cross-checked to press releases)

9. Q1 2026 earnings call (2026-04-29) — Greg Heckman (CEO), John Neppl (CFO). 2026 adjusted EPS guidance raised to $9.00–$9.50 (from $7.50–$8.00). Q1-26 adjusted EPS $1.83 (GAAP $0.35; −$1.28 MtM timing, −$0.20 Viterra costs). Adjusted segment EBIT $661M. Adjusted leverage 1.6× (vs 1.9× YE25); RMI > net debt by ~$400M. TTM adjusted ROIC 8%, ROIC 6.7% (adj 9%/7.2% ex-CIP/cash); cost of equity 7.2%; cash ROE 9.1%. Capex $1.5–1.7B, D&A ~$975M, net interest $620–660M. Viterra synergies “ahead of plan.” IFF soy-protein acquisition (~$105M) closed March 2026. Mid-East conflict impact on freight/bunker.
10. Q4/FY 2025 earnings call (2026-02-04) — initial 2026 guidance $7.50–$8.00; FY2025 adjusted FFO $1.7B, discretionary cash flow $1.25B, sustaining capex $485M; Q4-25 adjusted EPS $1.99 (GAAP $0.49; notable items incl. US pension settlement, Viterra costs, investment impairment); $551M / 6.75M shares repurchased in 2025; credit-rating upgrade; Investor Day announced for March 10, 2026.
11. Prior-quarter transcripts (2021–2025, via ROIC.ai list_earnings_calls) — cycle context.

Primary — Company events

12. Investor Day (March 10, 2026) — long-term outlook, Viterra synergy roadmap, and ~50%-of-discretionary-cash-flow capital-return framework (referenced on both transcripts; company IR).

Secondary / quantitative aggregators (reconciled to filings)

13. ROIC.ai MCP — multi-year income statement, balance sheet, cash-flow, profitability ratios, enterprise value, and valuation multiples (2020–2025). Used for trend/ratio cross-checks: ROE 25%→6%, ROIC 14%→4%, EBITDA margin 6.0%→2.8%, EV ~$32–37B, EV/EBITDA, P/B/P/S/P/E history. Third-party aggregated data; reconciled to the 10-K where material.
14. AZI price history CSV (azitrading.com/controls/download-data.php?t=BG) — 5-year split/dividend-adjusted OHLCV, EMAs, beta (~0.30). Basis for the price event map: 5yr range $64–$131 (ATH $131, June 2026), 52-wk $71–$131, latest ~$114.
15. AZI valuation_index — own-history percentile ranks: P/E 92nd, P/S 93rd, P/B 63rd, composite 83rd (P/E percentile inflated by trough GAAP EPS — read with P/B/P/S).
16. FactorsToday factor model — factor loadings (Value beta 0.72; Energy sector 0.40; OilPrice 0.38); leaderboard (lifetime max drawdown −77%, y1 return +54%, m3 negative); stock-info (beta 0.30, rs_12m 54, market cap ~$22.4B); related stocks (ADM 0.87, NTR, oil-refiner/ethanol ETFs). Third-party statistical estimates; facts reportable, interpretation regime-caveated.
17. AZI news feed — returned no scored articles for BG at pull time (noted as unavailable for this ticker at the pull moment); recent-events read built from filings/transcripts and public sources.

Peer / cross-read (public comparables)

18. ADM (Archer-Daniels-Midland) — closest public comp (factor similarity 0.87); industry/oilseed-processing framing and comp cross-read.
19. NTR (Nutrien) and CTVA (Corteva) — adjacent ag-input/crop public comparables.

Frameworks applied

20. Greenwald & Kahn, “Competition Demystified” — barriers-to-entry vs. pricing-power distinction; “economies of scale without customer captivity”; ROIC/market-share-stability moat tests.
21. Chancellor / Marathon, “Capital Returns” — supply-side capital-cycle analysis applied to crush-capacity additions and margin mean reversion.

Reconciliation note: where ROIC.ai / AZI / FactorsToday and the SEC filings differed on a material number, the filing governs. Diluted share count reconciled: FY2025 weighted-average ~166M (Viterra shares issued July 2), current shares outstanding ~197M (FactorsToday market cap ÷ price).